| 000 | 01400cam a2200181 4500500 | ||
|---|---|---|---|
| 005 | 20250121083956.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aFrenel, Jean-Sébastien _eauthor |
| 700 | 1 | 0 |
_a Zenatri, Morgan _eauthor |
| 700 | 1 | 0 |
_a Bachelot, Thomas _eauthor |
| 245 | 0 | 0 | _aResearch perspectives: Future prospects for the management of metastatic triple-negative breast cancers |
| 260 | _c2022. | ||
| 500 | _a3 | ||
| 520 | _aTriple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis. This disease, which has long been treated solely with chemotherapy, has recently been the subject of extensive research and therapeutic progress. The success of immunotherapy and antibody-drug conjugates (ADCs) has finally opened up new perspectives for advanced and early stages of the disease. In this review, we discuss the pathways being developed to improve the effectiveness of immunotherapy with novel approaches. We also review the numerous ADCs in development and their targets. Finally, we discuss the potential role of targeted therapies, such as PI3K AKT mTOR inhibitors, and hormone therapy approaches. | ||
| 786 | 0 | _nInnovations & Thérapeutiques en Oncologie | Volume 8 | Special Issue 1 | 2022-01-02 | p. 20-24 | 2431-3203 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2022-HS1-page-20?lang=en&redirect-ssocas=7080 |
| 999 |
_c504575 _d504575 |
||